Compass Therapeutics, Inc. (CMPX) — 10-Q Filings
All 10-Q filings from Compass Therapeutics, Inc.. Browse 7 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (7)
- 10-Q Filing — May 5, 2026
-
Compass Therapeutics' Net Loss Widens Amid R&D Surge, Bolstered by Equity Raise
— Nov 5, 2025 Risk: high
Compass Therapeutics, Inc. reported a net loss of $14.259 million for the three months ended September 30, 2025, an increase from a net loss of $10.481 million -
Compass Therapeutics Burns Cash on R&D, No Revenue in Q2
— Aug 11, 2025 Risk: high
Compass Therapeutics, Inc. reported no revenue for the six months ended June 30, 2025, consistent with the prior year period. The company's net loss for the six -
Compass Therapeutics Files Q1 2025 10-Q
— May 8, 2025 Risk: medium
Compass Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its clinical prog -
Compass Therapeutics Q3 2024 Update: Key Agreements Highlighted
— Nov 12, 2024 Risk: medium
Compass Therapeutics, Inc. filed its Q3 2024 10-Q report on November 12, 2024, covering the period ending September 30, 2024. The company's fiscal year ends on -
Compass Therapeutics Q2 2024 Update
— Aug 12, 2024 Risk: medium
Compass Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its ongoing clinical trials and strategic agreements, inc -
Compass Therapeutics Files 10-Q for Period Ending March 31, 2024
— May 13, 2024 Risk: medium
Compass Therapeutics, Inc. (CMPX) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Compass Therapeutics, Inc. filed its quarterly report (10-Q) for
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX